What is the prevalence of Churg Strauss Syndrome?

Churg-Strauss Syndrome, now clinically known as Eosinophilic Granulomatosis with Polyangiitis (EGPA), is a rare systemic vasculitis with an estimated prevalence of 10 to 14 cases per million adults. While incidence rates vary globally, it is estimated that 0.5 to 3.8 new cases occur per million people annually, though these numbers are likely underestimates due to diagnostic challenges.

Is Churg-Strauss Syndrome considered rare?

Yes, Churg-Strauss Syndrome is classified as a rare disease. Because it is a complex autoimmune condition affecting multiple organ systems, it is frequently misdiagnosed as severe asthma or other eosinophilic disorders. At DiseaseMaps.org, 126 people with Churg-Strauss Syndrome have joined our community, providing vital real-world data that helps complement clinical literature by highlighting the diagnostic journey of patients living with this condition.

What are the demographic trends of Churg-Strauss Syndrome?

The epidemiology of Churg-Strauss Syndrome reveals specific patterns regarding age and gender distribution:

• Age of Onset: The condition typically presents in adulthood, with a mean age of onset between 35 and 50 years; pediatric cases are significantly rarer.


• Gender Distribution: Most clinical studies suggest a relatively equal gender distribution, or a slight female predominance depending on the specific study cohort.


• Geographic Variation: Data indicates a higher reported incidence in Northern European populations compared to other regions, though this may reflect better diagnostic infrastructure rather than true biological prevalence.

Why is accurate data for Churg-Strauss Syndrome difficult to track?

Determining the exact prevalence of Churg-Strauss Syndrome is hindered by the lack of universal diagnostic criteria until recent years. Many patients experience a long "prodromal" phase characterized by asthma and allergic rhinitis, meaning they may live with the disease for years before the vasculitic phase of Churg-Strauss Syndrome manifests. Consequently, the true global burden remains difficult to quantify, as mild or early-stage cases often go undetected.

Next steps

• Consult a rheumatologist or pulmonologist with specific experience in ANCA-associated vasculitis.


• Join the Churg-Strauss Syndrome community at DiseaseMaps.org to connect with others and share experiences.


• Request a referral to a specialized vasculitis center for comprehensive management.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Eosinophilic granulomatosis with polyangiitis.


• Orphanet: Eosinophilic granulomatosis with polyangiitis.


• Vasculitis Foundation: Patient resources and clinical data on EGPA.


• PubMed/NCBI: Epidemiological studies on systemic vasculitis prevalence.